Результаты поиска - Foxley, Andrew

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentr... по Jones, Robert H, Casbard, Angela, Carucci, Margherita, Cox, Catrin, Butler, Rachel, Alchami, Fouad, Madden, Tracie-Ann, Bale, Catherine, Bezecny, Pavel, Joffe, Johnathan, Moon, Sarah, Twelves, Chris, Venkitaraman, Ramachandran, Waters, Simon, Foxley, Andrew, Howell, Sacha J

Полный текст Полный текст Полный текст

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolera... по Dean, Emma, Banerji, Udai, Schellens, Jan H. M., Krebs, Matthew G., Jimenez, Begona, van Brummelen, Emilie, Bailey, Chris, Casson, Ed, Cripps, Diana, Cullberg, Marie, Evans, Stephen, Foxley, Andrew, Lindemann, Justin, Rugman, Paul, Taylor, Nigel, Turner, Guy, Yates, James, Lawrence, Peter

Полный текст Полный текст Полный текст

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1(E17K)-Mutant, ER-Positive Metastatic Breast Cancer по Smyth, Lillian M., Tamura, Kenji, Oliveira, Mafalda, Ciruelos, Eva, Mayer, Ingrid A., Sablin, Marie-Paule, Biganzoli, Laura, Ambrose, Helen, Ashton, Jack, Barnicle, Alan, Cashell, Des, Corcoran, Claire, de Bruin, Elza C., Foxley, Andrew, Hauser, Joana, Lindemann, Justin P.O., Maudsley, Rhiannon, McEwen, Robert, Moschetta, Michele, Pass, Martin, Rowlands, Vicky, Schiavon, Gaia, Banerji, Udai, Scaltriti, Maurizio, Taylor, Barry S., Chandarlapaty, Sarat, Baselga, José, Hyman, David M.

Полный текст Полный текст Полный текст

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer по Smyth, Lillian M., Batist, Gerald, Meric-Bernstam, Funda, Kabos, Peter, Spanggaard, Iben, Lluch, Ana, Jhaveri, Komal, Varga, Andrea, Wong, Andrea, Schram, Alison M., Ambrose, Helen, Carr, T. Hedley, de Bruin, Elza C., Salinas-Souza, Carolina, Foxley, Andrew, Hauser, Joana, Lindemann, Justin P. O., Maudsley, Rhiannon, McEwen, Robert, Moschetta, Michele, Nikolaou, Myria, Schiavon, Gaia, Razavi, Pedram, Banerji, Udai, Baselga, José, Hyman, David M., Chandarlapaty, Sarat

Полный текст Полный текст Полный текст

AKT Inhibition in Solid Tumors With AKT1 Mutations по Hyman, David M., Smyth, Lillian M., Donoghue, Mark T.A., Westin, Shannon N., Bedard, Philippe L., Dean, Emma J., Bando, Hideaki, El-Khoueiry, Anthony B., Pérez-Fidalgo, José A., Mita, Alain, Schellens, Jan H.M., Chang, Matthew T., Reichel, Jonathan B., Bouvier, Nancy, Selcuklu, S. Duygu, Soumerai, Tara E., Torrisi, Jean, Erinjeri, Joseph P., Ambrose, Helen, Barrett, J. Carl, Dougherty, Brian, Foxley, Andrew, Lindemann, Justin P.O., McEwen, Robert, Pass, Martin, Schiavon, Gaia, Berger, Michael F., Chandarlapaty, Sarat, Solit, David B., Banerji, Udai, Baselga, José, Taylor, Barry S.

Полный текст Полный текст Полный текст

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers по Yap, Timothy A., Kristeleit, Rebecca, Michalarea, Vasiliki, Pettitt, Stephen J., Lim, Joline S.J., Carreira, Suzanne, Roda, Desamparados, Miller, Rowan, Riisnaes, Ruth, Miranda, Susana, Figueiredo, Ines, Rodrigues, Daniel Nava, Ward, Sarah, Matthews, Ruth, Parmar, Mona, Turner, Alison, Tunariu, Nina, Chopra, Neha, Gevensleben, Heidrun, Turner, Nicholas C., Ruddle, Ruth, Raynaud, Florence I., Decordova, Shaun, Swales, Karen E., Finneran, Laura, Hall, Emma, Rugman, Paul, Lindemann, Justin P.O., Foxley, Andrew, Lord, Christopher J., Banerji, Udai, Plummer, Ruth, Basu, Bristi, Lopez, Juanita S., Drew, Yvette, de Bono, Johann S.

Полный текст Полный текст Полный текст